Products - Structural heart defects | Topic | NICE

Showing 8 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 June 2024
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2023
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy [ID6354]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
8 January 2026
Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 January 2026
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Elamipretide for treating Barth syndrome in people of any age [ID6545]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC